C4 Therapeutics, Inc. (CCCC)
4.11
+0.11
(+2.75%)
USD |
NASDAQ |
Aug 24, 16:00
4.07
-0.04
(-0.97%)
After-Hours: 20:00
C4 Therapeutics Debt to Equity Ratio : 0.2299 for June 30, 2026
Debt to Equity Ratio Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2026 | 0.2299 |
| March 31, 2026 | 0.2495 |
| December 31, 2025 | 0.2338 |
| September 30, 2025 | 0.3981 |
| June 30, 2025 | 0.3615 |
| March 31, 2025 | 0.3298 |
| December 31, 2024 | 0.3044 |
| September 30, 2024 | 0.2765 |
| June 30, 2024 | 0.2769 |
| March 31, 2024 | 0.2699 |
| December 31, 2023 | 0.2884 |
| September 30, 2023 | 0.3341 |
| June 30, 2023 | 0.3582 |
| March 31, 2023 | 0.3256 |
| Date | Value |
|---|---|
| December 31, 2022 | 0.3013 |
| September 30, 2022 | 0.2767 |
| June 30, 2022 | 0.2505 |
| March 31, 2022 | 0.2398 |
| December 31, 2021 | 0.1101 |
| September 30, 2021 | 0.0569 |
| June 30, 2021 | 0.0547 |
| March 31, 2021 | 0.0866 |
| December 31, 2020 | 0.0816 |
| September 30, 2020 | 0.2284 |
| June 30, 2020 | |
| March 31, 2020 | |
| December 31, 2019 | -14.20 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| Cartesian Therapeutics, Inc. | -0.5099 |
| Beam Therapeutics, Inc. | 0.2317 |
| Rallybio Corp. | 0.00 |
| Q32 Bio, Inc. | 0.05 |
| Arrowhead Pharmaceuticals, Inc. | 2.956 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 359.40M |
| Total Liabilities (Quarterly) | 112.14M |
| Shareholders Equity (Quarterly) | 247.26M |
| Current Ratio | 5.449 |
| Net Debt Paydown Yield | 0.26% |